BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Li Y, Zhang Y, Fu M, Yao Q, Zhuo H, Lu Q, Niu X, Zhang P, Pei Y, Zhang K. Parthenolide induces apoptosis and lytic cytotoxicity in Epstein-Barr virus-positive Burkitt lymphoma. Mol Med Rep 2012;6:477-82. [PMID: 22735892 DOI: 10.3892/mmr.2012.959] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
Number Citing Articles
1 Mithöfer A, Maffei ME. General Mechanisms of Plant Defense and Plant Toxins. In: Gopalakrishnakone P, Carlini CR, Ligabue-braun R, editors. Plant Toxins. Dordrecht: Springer Netherlands; 2015. pp. 1-22. [DOI: 10.1007/978-94-007-6728-7_21-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
2 Mithöfer A, Maffei ME. General Mechanisms of Plant Defense and Plant Toxins. In: Carlini CR, Ligabue-braun R, editors. Plant Toxins. Dordrecht: Springer Netherlands; 2017. pp. 3-24. [DOI: 10.1007/978-94-007-6464-4_21] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
3 Liu Y, Huang S, Chen J, Wang LH. Microtubule depolymerization activates the Epstein–Barr virus lytic cycle through protein kinase C pathways in nasopharyngeal carcinoma cells. Journal of General Virology 2013;94:2750-8. [DOI: 10.1099/vir.0.058040-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
4 Pringproa K, Khonghiran O, Kunanoppadol S, Potha T, Chuammitri P. In Vitro Virucidal and Virustatic Properties of the Crude Extract of Cynodon dactylon against Porcine Reproductive and Respiratory Syndrome Virus. Vet Med Int 2014;2014:947589. [PMID: 24744959 DOI: 10.1155/2014/947589] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
5 Yiu SPT, Dorothea M, Hui KF, Chiang AKS. Lytic Induction Therapy against Epstein-Barr Virus-Associated Malignancies: Past, Present, and Future. Cancers (Basel) 2020;12:E2142. [PMID: 32748879 DOI: 10.3390/cancers12082142] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
6 Jakhmola S, Hazarika Z, Jha AN, Jha HC. In silico analysis of antiviral phytochemicals efficacy against Epstein-Barr virus glycoprotein H. J Biomol Struct Dyn 2021;:1-14. [PMID: 33438528 DOI: 10.1080/07391102.2020.1871074] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
7 Looi CK, Hii LW, Chung FF, Mai CW, Lim WM, Leong CO. Roles of Inflammasomes in Epstein-Barr Virus-Associated Nasopharyngeal Cancer. Cancers (Basel) 2021;13:1786. [PMID: 33918087 DOI: 10.3390/cancers13081786] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
8 Murata T. Regulation of Epstein-Barr virus reactivation from latency. Microbiol Immunol. 2014;58:307-317. [PMID: 24786491 DOI: 10.1111/1348-0421.12155] [Cited by in Crossref: 69] [Cited by in F6Publishing: 71] [Article Influence: 9.9] [Reference Citation Analysis]
9 Kanakry JA, Ambinder RF. EBV-related lymphomas: new approaches to treatment. Curr Treat Options Oncol 2013;14:224-36. [PMID: 23549980 DOI: 10.1007/s11864-013-0231-y] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 6.0] [Reference Citation Analysis]
10 Karam L, Abou Staiteieh S, Chaaban R, Hayar B, Ismail B, Neipel F, Darwiche N, Abou Merhi R. Anticancer activities of parthenolide in primary effusion lymphoma preclinical models. Mol Carcinog 2021;60:567-81. [PMID: 34101920 DOI: 10.1002/mc.23324] [Reference Citation Analysis]
11 Charostad J, Nakhaie M, Dehghani A, Faghihloo E. The interplay between EBV and KSHV viral products and NF-κB pathway in oncogenesis. Infect Agent Cancer 2020;15:62. [PMID: 33072180 DOI: 10.1186/s13027-020-00317-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
12 Sztiller-Sikorska M, Czyz M. Parthenolide as Cooperating Agent for Anti-Cancer Treatment of Various Malignancies. Pharmaceuticals (Basel) 2020;13:E194. [PMID: 32823992 DOI: 10.3390/ph13080194] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
13 Murata T, Tsurumi T. Switching of EBV cycles between latent and lytic states: Regulation of EBV reactivation. Rev Med Virol 2014;24:142-53. [DOI: 10.1002/rmv.1780] [Cited by in Crossref: 86] [Cited by in F6Publishing: 75] [Article Influence: 9.6] [Reference Citation Analysis]